Premium
Identification of HIV‐1 Tat peptides for future therapeutic angiogenesis
Author(s) -
Ismail Mahmoud,
Henklein Peter,
Huang Xiaohua,
Braumann Chris,
Rückert Ralph I.,
Dubiel Wolfgang
Publication year - 2006
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2006.00682.x
Subject(s) - angiogenesis , therapeutic angiogenesis , umbilical vein , matrigel , cancer research , pharmacology , endothelial stem cell , plasminogen activator , medicine , biology , immunology , neovascularization , biochemistry , in vitro
Therapeutic angiogenesis represents a novel approach to treat critical limb ischemia when revascularization is no more an option. The clinical use of the vascular endothelial growth factor is questioned, because of its side effects. This study was designed to identify and characterize human immunodeficiency virus type 1 (HIV‐1) Tat‐derived peptides based on their pro‐angiogenic properties. A series of Tat‐derived peptides were synthesized containing mutations in the basic domain. To minimize side effects Tat peptides were selected exerting no effects on the proteasome and on the viability of human umbilical vein endothelial cells (HUVEC). Tatpep5, 15, and 16 increased the endogenous levels of the pro‐angiogenic transcription factors c‐Jun and SP‐1 as well as the production of the plasminogen activator inhibitor‐1 (PAI‐1) by HUVEC. A significant induction of endothelial cell invasion was observed upon treatment of HUVEC with Tat peptides. In addition, selected Tat peptides induced tube formation by HUVEC as visualized and quantified in a Matrigel matrix. Our data demonstrate that the selected Tat peptides fulfill essential criteria for pro‐angiogenic substances. They represent the basis for the development of novel pro‐angiogenic drugs for future therapeutic angiogenesis, which might be applied for treatment of unreconstructible critical limb ischemia.